These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24057040)

  • 1. An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
    Launay-Vacher V
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1361-7. PubMed ID: 24057040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
    Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
    J Clin Pharmacol; 2013 Feb; 53(2):192-201. PubMed ID: 23436264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.
    Melichar B; Študentová H; Kalábová H; Vitásková D
    Immunotherapy; 2014; 6(7):811-9. PubMed ID: 25290414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
    Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.
    Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697
    [No Abstract]   [Full Text] [Related]  

  • 6. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
    Gujral DM; Lloyd G; Bhattacharyya S
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):446-7. PubMed ID: 23583229
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen.
    Bittner B; Richter WF; Hourcade-Potelleret F; McIntyre C; Herting F; Zepeda ML; Schmidt J
    Arzneimittelforschung; 2012 Sep; 62(9):401-9. PubMed ID: 22918857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
    Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant trastuzumab for HER2-positive early breast cancer.
    Palmieri FM; Myatt CV; Perez EA
    Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
    Van den Nest M; Glechner A; Gold M; Gartlehner G
    Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
    Brufsky A
    Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer.
    Burris HA; Tibbitts J; Holden SN; Sliwkowski MX; Lewis Phillips GD
    Clin Breast Cancer; 2011 Oct; 11(5):275-82. PubMed ID: 21729661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.
    Ramić S; Asić K; Balja MP; Paić F; Benković V; Knežević F
    Anticancer Res; 2013 Jun; 33(6):2509-15. PubMed ID: 23749902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
    Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
    J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
    Khasraw M; Bell R
    Expert Rev Anticancer Ther; 2012 Aug; 12(8):1005-13. PubMed ID: 23030220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.